News - Pradaxa, Elan


Current filters:


Popular Filters

1 to 25 of 72 results

Boehringer analysis finds better outcome for Pradaxa compared to warfarin

Boehringer analysis finds better outcome for Pradaxa compared to warfarin


Boehringer Ingelheim has released new data showing better survival prognosis following a major bleeding…

Boehringer IngelheimHematologyPharmaceuticalPradaxaResearch

Boehringer Ingelheim plans to expand body of evidence for Pradaxa


German family-owned drug major Boehringer Ingelheim has announced new milestones for the novel oral anticoagulant…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaResearch

Pradaxa sNDA for DVT and PE accepted by FDA


The US Food and Drug Administration has accepted for review German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

Elan board agrees $8.6 billion takeover bid


US health care company Perrigo (NYSE: PRGO) revealed this morning that Ireland-based drugmaker Elan Corp…

ElanGenericsMergers & AcquisitionsPerrigoPharmaceuticalTysabri

Elan posts financials, as it explores sale of the company


Ireland-based Elan Corp (NYSE:ELN) today reported its second quarter 2013 financial results, showing…

ElanFinancialMergers & AcquisitionsPharmaceuticalTysabri

US FDA fast-tracks Elan's Alzheimer's drug candidate


Ireland-based Elan Corp (NYSE: ELN) says that the US Food and Drug Administration has granted Fast Track…

ElanELND005GlobalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulation

Royalty pulls plug on Elan buy (for now?); analysts' view on what comes next


In the ongoing hostile takeover saga, US private equity firm Royalty Pharma has withdrawn its request…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

AOP Orphan spins off stake in Activartis as Elan shareholders vote down acquisition


In the wake of yesterday's shareholders vote against Irish drugmaker Elan Corp's (NYSE: ELN) planned…

ActivartisAOP OrphanElanMergers & AcquisitionsOncologyPharmaceutical

Royalty Pharma hostile bid lapses as Elan shareholders vote for share repurchase but not Theravance, AOP or ELND005 deals


At the company's Extraordinary General Meeting held earlier today (June 17), shareholders of Ireland-based…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan puts up formal "for sale" notice


Ireland-based Elan Corp (NYSE:ELN), which has been the subject of a hostile takeover campaign by private…

Biogen IdecElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty bid for Elan could be withdrawn; J&J sells 25.4 million Elan shares


Ireland-based hostile takeover target Elan (NYSE: ELN) fell 5.2% to 9.29 euros on June 13, the most in…

ElanJohnson & JohnsonMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan board unreservedly rejects Royalty's increased tender offer


Ireland-based drugmaker Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma hikes offer for Elan to $13 a share, plus CVR of up to $2.50


Ireland-based Elan Corp (NYSE: ELN) saw its shares to 5.3% to $13.35 by mid morning last Friday (June…

ElanMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan details further inadequacy of Royalty Pharma's revised offer; takes legal action


The saga of Royalty Pharma's hostile attempts to acquire Ireland-headquartered Elan Corp (NYSE: ELN)…

ElanLegalMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan tells shareholders it is worth up to $20.80 a share and they should not accept Royalty's $12.50 offer


In the ongoing saga of Royalty Pharma's takeover attempts, Ireland-based Elan (NYSE: ELN) has communicated…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Elan rejects Royalty Pharma's increased bid; prices Senior Notes offering


Ireland-based takeover target Elan Corp (NYSE: ELN) says that its board of directors, after careful review…

ElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Royalty Pharma ups bid for Elan to $12.50 a share


ot on the heels of Ireland-based drugmaker Elan Corp's (NYSE: ELN) own acquisition plans (it is to buy…

ElanMergers & AcquisitionsPharmaceuticalRoyalty Pharma

Elan makes "transformational" acquisitions and a divestment


Ireland-headquartered Elan Corp (NYSE: ELN) (Elan) this morning announced a series of transactions designed…

AOP OrphanElanELND005Mergers & AcquisitionsNewBridge PharmaceuticalsPharmaceuticalSperanza Therapeutics

Elan reports 1st-qtr operating loss


Ireland-based Elan Corp (NYSE: ELN), which has again rejected takeover approach form Royalty Pharma and…


1 to 25 of 72 results

Back to top